Ken Griffin Acer Therapeutics Inc. Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.75 - $1.14 $2,519 - $3,829	3,359 New	3,359 $3,000
Q4 2022 Feb 14, 2023	SELL	$1.13 - $4.15 $57,944 - $212,803	-51,278 Reduced 98.38%	847 $2,000
Q3 2022 Nov 14, 2022	BUY	$1.28 - $1.6 $37,825 - $47,281	29,551 Added 130.91%	52,125 $72,000
Q2 2022 Aug 15, 2022	SELL	$1.19 - $3.04 $16,787 - $42,885	-14,107 Reduced 38.46%	22,574 $28,000
Q3 2021 Nov 15, 2021	SELL	$2.3 - $2.86 $56,642 - $70,433	-24,627 Reduced 40.17%	36,681 $94,000
Q1 2021 May 17, 2021	BUY	$2.47 - $4.39 $110,648 - $196,658	44,797 Added 271.32%	61,308 $191,000
Q4 2020 Feb 16, 2021	SELL	$2.34 - $2.99 $1,326 - $1,695	-567 Reduced 3.32%	16,511 $43,000
Q2 2019 Aug 14, 2019	BUY	$3.45 - $26.86 $58,919 - $458,715	17,078 New	17,078 $67,000

365

Ticker ACER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,100,000
Description
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mu...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.